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Background: Randomized controlled trials and retrospective studies in ANCA-associated vasculitis (AAV) concurred
that rituximab (RTX) is effective to induce and maintain remission. Infections and hypogammaglobulinemia during
RTX were usually infrequent and uncomplicated. But in the Tromsø study cohort, 45 % of patients with
granulomatosis with polyangiitis (GPA) developed hypogammaglobulinemia during RTX maintenance leading
to its discontinuation in 62 %.
Methods: To explain these differences in outcome when using RTX in AAV to maintain remission, we used
statistical structural methods to compare the Tromsø study cohort with other published cohorts.
Results: GPA patients’ characteristics of the Tromsø study cohort were not so different compared with other
cohorts. Rates of hypogammaglobulinemia and discontinuation of RTX seemed closely related to the cut-off
used and to the levels of immunoglobulin (Ig) at baseline. Combination of low IgG serum levels at baseline
(7.7 g/L) and low cut-off to define hypogammaglobulinemia in the Tromsø study cohort explained the high
rate of hypogammaglobulinemia and discontinuation of RTX.
Conclusions: Patients’ characteristics in the Tromsø study cohort were not skewed, apart from IgG levels. Low
IgG level at baseline seemed to contribute the most to hypogammaglobulinemia and its complications.
Keywords: ANCA-associated vasculitis, Rituximab, Induction, Maintenance, Immunoglobulin,
Hypogammaglobulinemia, Discontinuation, Adverse event, Principal component analysis, Correspondence
analysis
Background
Granulomatosis with polyangiitis (GPA) is an ANCA-
associated vasculitis (AAV) affecting usually the small and
medium vessels and is closely related to proteinase3-
ANCA (PR3-ANCA). GPA often involves the upper and
lower airways tracts and kidneys and was a fatal disease
prior to the use of cyclophosphamide (CYC) [1].
Rituximab (RTX) is a chimeric monoclonal antibody
against CD20 that depletes B cells [2] and is effective in
inducing and maintaining remission in AAV patients in
randomized controlled studies [3–5]. In two
retrospective studies of remission maintenance with
RTX, severe infections and hypogammaglobulinemia
were frequent adverse events: 26–29 % had severe infec-
tions and 41–45 % had hypogammaglobulinemia [6–8].
However interpretation of the risk of hypogammaglobu-
linemia and its practical implications differed between
the two studies. In the Tromsø study cohort, 17 % re-
ceived intravenous immunoglobulin (IVIG) replacement
and 62 % who developed hypogammaglobulinemia dis-
continued maintenance remission with RTX [8].
To explain differences in outcome, we compared using
statistical structural methods the patients’ characteristics
of the Tromsø study cohort with other published studies
of induction and maintenance with RTX in AAV.
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Methods
Identification of induction and maintenance studies
Two studies from the Northern Norwegian vasculitis
register that was approved in 2001 by the Regional Eth-
ical Committee for Medical and Health Research Ethics
(REK-V 41/2001) were included [6, 8]. Patients (or the
patients’ parents or guardians in case of children) gave
written informed consent in accordance to the declar-
ation of Helsinki at registry inclusion.
All other induction and maintenance studies with
RTX in AAV were retrieved either from searching
PubMed (www.ncbi.nlm.nih.gov/pubmed) in January
2015 using indexing terms ANCA vasculitis, rituximab
maintenance and induction, or from reviewing the refer-
ence lists.
All studies of nine or more AAV patients were in-
cluded in the analysis. Eighteen induction [3, 4, 6, 9–24]
and 11 maintenance studies [5–8, 24–32] were identi-
fied. Definition of severe infections was similar in all
studies, while definition of hypogammaglobulinemia
differed.
Statistical analysis
Principal component analysis (PCA) finds the best linear
combinations of important variables at baseline. Number
of patients, age, proportion of men, PR3-ANCA status,
kidney and lung involvement, Birmingham vasculitis
score (BVAS) at baseline, proportion of patients exposed
to CYC and type of RTX induction regimen were in-
cluded in the PCA of induction studies. Number of pa-
tients, age, PR3-ANCA status, kidney and lung
involvement, exposure to CYC, disease duration prior
RTX and follow-up in months were included in the PCA
of maintenance studies. Correspondence analysis (CA)
of adverse events during RTX maintenance included
studies that reported the risks of both severe infections
and hypogammaglobulinemia.




Ten studies out of 18 were included in the PCA. Missing
data from studies not included in the PCA were PR3-
ANCA status [20, 21, 23], lung involvement [3, 22], CYC
exposure [13, 17] and BVAS [12, 20] (Table 1 and Fig. 1).
All studies concluded that RTX was effective in inducing
remission in AAV patients, even though patients’ charac-
teristics and induction regimen were different. The two
first PCA dimensions explained 59 % of the variance of
the cohorts’ characteristics included in the analysis.
Table 1 Characteristics of ANCA-associated vasculitis patients who received rituximab for remission induction















% y % % % % % mo mo % g/L g/L % %
Linköping, Sweden 9 56 59 78 78 44 NA 100 36 12 0 6 8.4 6.4 NR 0 10
Rochester, US 10 70 57 100 70 40 10 100 59 9 0 6 NR NR NR 20 11
MC, UK 65 52 47 57 10 40 20 97 72 20 49 NR 7.9 8.0 0 20 12
Boston, US 39 49 60 62 NR NR NR NR 67 18 90 1 NR NR 0 3 13
Bad-Bramstedt Germany 59 59 54 86 44 41 46 100 37 7 0 11 8.6 6.9 12 26 14
Freiburg, Germany 37 57 62 81 60 81 NR 92 99 30 81 13 9.9 9.0 27 16 24
Goteborg, Sweden 29 52 51 97 62 59 38 100 31 21 0 6 NR NR NR 10 15
Stockholm, Sweden 16 56 60 81 50 50 NR 100 68 20 38 10 NR NR NR 38 16
London UK 2014 19 26 61 53 53 32 NR NR 40 11.5 0 7 NR NR 0 0 17
Munich, Germany 17 59 58 76 71 59 53 76 40 24 0 13 NR NR NR 24 18
Cleveland, US 105 48 49 75 58 83 NA 88 55 23 73 4 NR NR NR 7 19
London, UK 2009 10 50 49 NR 40 0 70 90 78 12 100 NR NR NR NR 0 20
Torino, Italy 11 55 58 NR 64 27 NR 82 22 NR 0 23 8.0 6.7 NR NR 21
London, UK 2011 23 52 59 70 100 NR NR 100 1 36 100 21 NR NR 4 9 22
Registry Germany 58 48 50 NR 45 59 19 60 54 18 47 13 NR NR NR 7 23
RAVE US 99 46 54 67 66 52 NR 42 30 6 0 9 NR NR NR 7 4
RITUXIVAS EUVAS 33 52 68 53 100 NR NR 100 1 12 0 19 NR NR 3 19 3
Tromsø, Norway 29 52 50 86 59 66 62 97 57 49 100 10 7.7 NR NR NR 8
BVAS Birmingham Vasculitis Activity Score, CYC cyclophosphamide, FU follow-up during maintenance remission with rituximab, HypoG rate of hypogammaglobulinemia,
MCmulticentric study, N number of patients, NR not reported, RTX rituximab, Ref reference, SI rate of severe infection
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The RAVE and Cleveland Clinic studies recruited the
most patients [4, 19]. The two 1g- RTX infusions given
one fortnight apart were used more often at induction in
the studies from Freiburg and Tromsø [8, 24].
Patients in the Tromsø cohort only had GPA, were
more often PR3-ANCA positive, had more lung and less
kidney involvement, received more frequently CYC and
had a higher BVAS at baseline (Fig. 1).
Maintenance
The PCA did not include two studies that reported nei-
ther age [31] nor exposure to CYC [29]. Studies were
very different in term of patients’ characteristics at base-
line, however all reported decreased disease activity and
relapse rates during RTX maintenance (Table 2 and
Fig. 2). The two first PCA dimensions explained 64 % of
the variance of the cohorts’ characteristics included in
the analysis.
Studies from Freiburg [24] and two other multicentric
French studies [5, 32] were closely related, as their pa-
tients were older at RTX induction, had more kidney and
lung involvement and had the shortest follow-up after
RTX. Almost all patients were PR3-ANCA positive in the
studies from Mayo Clinic and Nottingham [25, 28]. Co-
horts from Tromsø and Paris were closest to the centroid
(point 0) [8, 26].
Patients in the Tromsø cohort only had GPA, were
younger, more often PR3-ANCA positive and received
more frequently CYC prior to RTX (Fig. 2).
Severe infection and hypogammaglobulinemia during
maintenance
A total of 18 % (range 11–33 %) of patients had severe in-
fections during RTX maintenance [5–7, 24, 29–32]; 18 %
(2 – 45 %) developed hypogammaglobulinemia [7, 8, 24,
25, 29, 30]. The CA included five cohorts [6–8, 24, 29, 30]
Fig. 1 Principal component analysis of rituximab induction studies. 1: DE-Bad-Bramstedt [14]; 2: US-Cleveland [19]; 3: DE-Freiburg [24]; 4: DE-Munich
[18]; 5: SE-Gothenburg; [15]; 6: SE-Stockholm [16]; 7: RAVE study [4]; 8: US-Rochester [11], 9: SE-Linköping [10]; 10: NO-Tromsø [6]. Age: age in years;
BVAS: Birmingham Vasculitis Activity Score; CYC: proportion of patients exposed to cyclophosphamide; Kidney: proportion of patients with
kidney involvement; Lung: proportion of patients with lung involvement; Men: proportion of men in studies; N: number of patients
in studies; PR3: proportion of patients who are PR3-ANCA positive; RTX_1gx2: proportion of patients who received rituximab 1g twice
given one fortnight apart (rheumatoid arthritis protocol)
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Table 2 Characteristics of ANCA-associated vasculitis patients who received rituximab for remission maintenance
Study place N Age Men PR3-
ANCA




FU mo IgG before IgG after SI HypoG Ref
y % % % g g % % % mo g/L g/l % %
Nottingham, UK 11 41 64 100 100 NR 8 55 46 NR 14 72 32 NR NR NR 9 25
Paris 2011, France 28 51 60 68 100 48 NR 32 64 14 15 84 38 7.8 7.0 11 11 26
Rochester, US 53 46 47 98 100 NR NR 42 49 NR 5 120 53 8.4 5.7 NR NR 28
Freiburg, Germany 37 62 57 81 92 12 NR 60 81 NR 13 99 30 9.9 NR 16 27 24
Boston, US 172 60 45 43 NR NR NR 62 44 NR 2 NR 25 NR NR 15 10 29
Paris 2014, France 66 50 49 80 89 29 4.6 21 47 14 10 67 34 8.3 7.5 14 2 30
Uppsala, Sweden 12 NR 42 100 100 61 NR 50 100 42 9 35 79 8.5 6.8 33 NR 31
MC, France 80 53 NR 84 98 13 NR 55 71 10 7 54 18 NR NR 15 NR 32
Mainritsan, France 57 54 65 77 100 7.3 2.5 70 58 NR NR 3 28 6.1 6.9 19 NR 5
Cambridge, UK 69 52 41 74 91 13.5 6 12 29 12 NR 60 59 9.3 8.0 29 41 7
Tromsø, Norway 29 50 52 86 97 17 9 59 66 62 10 57 49 7.7 4.9 24 45 8
BVAS Birmingham Vasculitis Activity Score, CYC cyclophosphamide, FU follow-up during maintenance remission with rituximab, HypoG rate of hypogammaglobulinemia, MC
multicentric study, N number of patients, NR not reported, Orb-Subg frequency of orbital-subglottic involvement, RTX rituximab, Ref reference, SI rate of severe infection
Fig. 2 Principal component analysis of rituximab maintenance studies. 1: DE-Freiburg [24]; 2: FR-MC [32]; 3: FR-MAINRITSAN study [5]; 4: NO-Tromsø
[6, 8]; 5: UK-Cambridge [7]; 6: US-Rochester [28]; 7: FR-Paris 2012 [26]; 8: UK-Nottingham [25]; 9: FR-Paris 2014 [30]. Age in years; CYC: proportion of
patients exposed to cyclophosphamide; Follow_up: follow-up of remission maintenance with rituximab; Kidney: proportion of patients with
kidney involvement; Lung: proportion of patients with lung involvement; N: number of patients included in the studies; PR3: proportion of patients with
positive PR3-ANCA; Time_RTX: disease duration prior to rituximab
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as data of both severe infection and hypogammaglobuline-
mia were lacking in most studies. The Tromsø and Cam-
bridge study cohorts had more severe infection and
hypogammaglobulinemia [6–8] compared with Freiburg,
Paris and Boston [24, 29, 30] (Fig. 3). Risks of severe infec-
tions and hypogammaglobulinemia were equivalent in the
studies of Cambridge and Tromsø [6–8]. While severe
hypogammaglobulinemia occurred in 7 % of the patients
in the Cambridge cohort [7], hypogammaglobulinemia led
to RTX discontinuation in 62 % and 53 % in the Tromsø
and Boston cohorts [8, 29].
Ig levels were lower in patients from the Tromsø study
cohort both at baseline and during RTX maintenance:
IgG 7.7 compared with > 8.3 g/L at baseline in the other
studies [7, 24, 29, 30] and IgG 4.9 during maintenance
compared with > 7.0 in Boston [29], 7.5 in Paris [30], 8.0
in Cambridge [7] and 9.0 in Freiburg [24].
Discussion
The Tromsø study cohort only included GPA patients;
they were more frequently PR3-ANCA positive and were
often exposed to CYC compared with other cohorts. Pa-
tients’ characteristics of the Tromsø cohort were similar
to Freiburg during induction [24] and to an older cohort
from Paris during maintenance [26]. The Tromsø study
cohort seemed representative of maintenance studies
since it was close to the centroid of the PCA.
In AAV, the risks of hypogammaglobulinemia and of
severe infection seemed equivalent at 18 % during remis-
sion maintenance with RTX. While severe infection was
defined alike in all studies, the definition of hypogam-
maglobulinemia was not standardized and identified
patients with different Ig serum levels conferring dif-
ferent risk to receive IVIG and to discontinue RTX.
Hypogammaglobulinemia cutoff was lowest in the
Boston study: total IgG < 4 g/L [29] vs. IgG < 6 in
Cambridge [7], IgG < 7 [24] in Freiburg, total Ig < 6
(corresponding to IgG < 5 g/L) in Tromsø [8] and
total Ig < 7 g/L in Paris [30]. Difference in cutoffs ex-
plained the difference in results between studies, but
hypogammaglobulinemia in the Tromsø study was
still more frequent and severe.
Fifty three and 62 % discontinued RTX maintenance
due to hypogammaglobulinemia in the Boston and
Tromsø cohorts [8, 29]. However the risk of hypogam-
maglobulinemia was four times higher in the Tromsø
cohort since the Boston study used a lower cutoff to de-
fine hypogammaglobulinemia [29].
The Cambridge and Tromsø studies had an increased
risk of hypogammaglobulinemia, respectively 41–45 %
[6–8]. However the impact of hypogammaglobulinemia
was more severe in the Tromsø study. In the Tromsø
study, patients had lower IgG levels during RTX main-
tenance and 17 % required intravenous immunoglobulin
Fig. 3 Correspondence analysis of adverse events in studies on RTX maintenance in AAV. Hypog: hypogammaglobulinemia; No_Hypog: absence
of hypogammaglobulinemia; No_SI: absence of severe infection; SI: severe infection. 1: Tromsø Norway [6, 8]; 2: Cambridge UK [7]; 3: Boston USA
[29]; 4: Freiburg Germany [24]; Paris France [30]
Besada BMC Musculoskeletal Disorders  (2016) 17:6 Page 5 of 7
(IVIG) replacement [8]. Only 7 % required IVIG in the
Cambridge study [7].
PR3-ANCA status and exposure to CYC prior to RTX
were similar in the Tromsø and Cambridge cohorts.
Nevertheless others factors, such as organ involvement
and treatment strategy during remission maintenance,
could also explain the differences in severity of hypo-
gammaglobulinemia between both studies. GPA patients
in the Tromsø study had more lung and kidney involve-
ment than in Cambridge. They also used concomitant
immunosuppressive drugs for a median of two years and
continued with pre-emptive RTX maintenance for a
median of four years. While in the Cambridge study,
patients did not use concomitant immunosuppressive
drugs, received RTX remission maintenance during
two years and were only re-treated with RTX in case
of relapse [7].
Conclusions
In summary, GPA patients’ characteristics in the Tromsø
cohort were not skewed compared with the other co-
horts, apart from IgG levels. In agreement with a previ-
ous study on RTX use in autoimmune diseases [33], low
IgG level at baseline seemed to contribute the most to
hypogammaglobulinemia and its complications during
RTX maintenance in AAV.
Ethics approval and consent to participate
Human data originated from the Northern Norwegian vas-
culitis register that was approved in 2001 by the Regional
Ethical Committee for Medical and Health Research Ethics
(REK-V 41/2001). Patients (or the patients’ parents or
guardians in case of children) gave written informed con-
sent in accordance to the declaration of Helsinki at registry
inclusion.
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